DragonFly-T 1st Transcatheter Tricuspid Valve Repair Surgery: Marks Major Breakthrough in the Field of Tricuspid Valve Intervention in China

December 21, 2020

DragonFly-T Transcatheter Tricuspid Valve successful repair surgery was performed in China by Professor Wang Jian‘an’s team from the Second Hospital of Zhejiang University School of Medicine.

This is the first self-developed product for trans-femoral tricuspid regurgitation repair in China, and the first transcatheter tricuspid valve repair in China, marking a major breakthrough in the field of tricuspid valve intervention in China.

The patient was a 79-year-old woman who was admitted with “recurrent chest tightness for more than 1 year” and was diagnosed with atrial fibrillation, functional tricuspid regurgitation, class IV cardiac function, and ascites. Preoperative transthoracic echocardiography (TTE) revealed extremely severe tricuspid regurgitation, bilateral atrial enlargement, tricuspid regurgitant width about 0.84 cm, effective tricuspid regurgitant orifice area 0.84 cm2, pulmonary artery systolic pressure 39 mmHg.

Although the patient had undergone adequate and optimal medication, she still had recurrent heart failure episodes, and the risk of surgical open-heart surgery was extremely high, and she could not be effectively treated in several hospitals. Prof. Wang Jian‘an’s team decided to perform a minimally invasive tricuspid valve repair via the femoral vein route using the DragonFly-T™ Transcatheter Tricuspid Valve Clamping System.

The operation was performed under general anesthesia with a femoral vein approach. The clip was delivered to the right ventricle under transesophageal echocardiography and X-ray guidance to capture and clamp the anterior and septum tricuspid valve leaflets and close the valve clip. A total of three valve clips were implanted, and the clips were in good position and function. The tricuspid regurgitation grade decreased from 5+ preoperatively (Figure 2)  to 1+ immediately postoperatively (Figure 3), and the hepatic venous flow improved significantly (Figure 4). The operation was completed successfully.

The patient was able to move around on her own the day after operation, and her existing discomfort was significantly reduced. She was discharged from the hospital two days after the operation, and a transthoracic ultrasound examination before discharge showed mild tricuspid regurgitation with a regurgitation grade of 1+ (Figure 5).

Professor Wang Jian‘an said after the operation: “The population of tricuspid regurgitation patients in China is wide and often with many comorbidities, the current clinical medication treatment is less effective, and the surgical treatment of tricuspid regurgitation remain high risky, and the recommendation of tricuspid regurgitation in clinical guidelines still absence. In this patient, we achieved a very promising result with the DragonFly-T™ device and look forward to further studies to demonstrate the effectiveness and safety of DragonFly-T™.”

Valgen Medtech is located in Binjiang, Hangzhou, China. The company focuses on the development of treatment technologies related to structural heart disease, especially mitral and tricuspid valves, and provides systemic solutions for mitral and tricuspid valve lesions (Tool Box Concept).

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy